re: 4. preliminary final report. 4 http://stocknessmonster.com/news-item?S=PBT&E=ASX&N=223248
Extract: Drug Development: " PBT-1: Double blind proof-of-concept clinical trial and extension clinical trial complete. Results of the initial double blind portion of the study were submitted and published in the prestigious specialist journal Archives of Neurology in December 2003.
· PBT-2: Proprietary lead molecule selected and formal development initiated. Formal toxicology is targeted to complete in 2004 and if successful this will allow clinical trials to initiate in early 2005
· Design and synthesis is underway for next generation compounds for Alzheimer ’s disease (NG-1) and Parkinson’s Disease (NG-2). Multiple candidates for NG-1 have been identified and a development candidate is targeted in 2004.
· Immunotherapy: Research progressing and on track for initial proof of principle trials to initiate in 2004.
· Chemistry and Discovery program: Over 400 MPACs (metal-protein attenuating compounds) now designed, synthesised and tested in preclinical models.
Over 100 MPACs of new structural classes from PBT-1 and PBT-2 synthesised and tested".
PBT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)